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ABSTRACT. Many active anti-arthritic natural substances are revealed into the past years. The aim of study was 
to assess the combined efficacy of methylsulfonylmethane (MSM) with thiocolchicoside (Th) (compound MTh) and 
MSM alone against adjuvant-induced arthritis (AA) in rats. In the first experiment 30 rats and in the second - 21 rats 
were randomly divided into 6 groups: I gr. - AA + MSM (77 mg/kg), II and V gr. - AA + diclofenac (DF), III and VI 
gr. - the control AA groups without treatment, IV gr. - MTh (38 mg/kg). DF (1 mg/kg) in both experiments was used as 
a reference drug. 6 rats were as the healthy control group. AA rats were treated from day 0 to 17. All preparations were 
suspended in 0.5 ml of 1℅ starch gel and injected orally 5 days a week. Body weight and joint swelling were monitored 
3 times a week. Development of polyarthritis, blood indices, pro-/antioxidant activity and pro-inflammatory cytokines 
in blood serum, and histopathology of the liver and paw were assessed at the end of experiment. MSM significantly 
decreased joint swelling on days 3 and 13. MTh in twice lower dose more markedly suppressed joint swelling and also 
significantly reduced the changes in soft periarticular tissues, synovium and cartilage as compared to the control AA 
group. Both preparations alleviated infiltration with inflammatory cells and synovial proliferation, as well as protected 
cartilage destruction and decreased pannus formation. MSM and MTh improved the blood indices and insignificant-
ly suppressed IL-17. They markedly decreased the level of malondialdehyde (MDA). Some anti-oxidant activity of 
preparations was also confirmed. No toxic effects on the liver were revealed. MSM and MTh attenuated the develop-
ment of AA in rats. Combination therapy was more effective than single MSM and required the twice lower doses to 
receive the beneficial anti-arthritic effect. Both preparations could be the potential preventive or therapeutic candidates 
for the treatment of autoimmune processes in combination with other drugs.
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Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disorder character-
ized by severe pain, inflammation of synovial joints 
with neovascularization, pannus formation and de-
struction of cartilage. Activated rheumatoid synovial 
fibroblasts (RASFs) actively participate in RA syno-
vitis (Huber et al., 2006) and aggressively prolifer-
ate to form a pannus, which produce inflammatory 
mediators (Han et al., 2003). Defective apoptosis of 
RASFs is an important mechanism contributing to sy-
novial hyperplasia in RA (Pattacini et al., 2010; Xiao 
et al., 2012). 
The conventional drug treatment of RA consists 
from analgesic, non-steroidal anti-inflammatory 
drugs (NSAIDs), disease-modifying anti-rheumatic 
drugs (DMARDs), corticosteroids to biologics. How-
ever, a common effect of long-term therapy is the de-
velopment of resistance to treatment and an increased 
occurrence of adverse effects. In the past several 
years, there has been a vast increase in a number of 
complementary drugs purported to have joint-protest-
ing and the antioxidant and free radicals scavenging 
properties (Kripa et al., 2011; Lopez, 2012; Ezaki et 
al., 2013), because many studies have validated a role 
of oxidative stress in RA (Filipin et al., 2008; Kundu 
et al., 2012; Stamp et al., 2012; Biniecka et al., 2011). 
Agents that we investigated are methylsulfonyl-
methane (MSM) and MSM in combination with Thio-
colchicoside (Th) (compound with code name MTh). 
MSM is a non-toxic, natural compound widely 
used as a dietary supplement for its beneficial effects 
against various diseases, especially arthritis to re-
duce arthritic and rheumatic pain (Kim et al., 2006; 
Ameye and Chee, 2006) and (often in combination 
with glucosamine and chondroitin) to treat or prevent 
osteoarthritis (Gregory et al., 2008). Previous stud-
ies demonstrated that MSM possessed antioxidant 
and anti-inflammatory properties (Kim et al., 2009; 
Maranon et al., 2008; Nakhostin-Roohi et al., 2011; 
Amirshahrokhi et al., 2013) by increasing antioxidant 
enzyme levels and reducing malondialdehide (MDA), 
myeloperoxidase (MPO) and TNF-α (Amirshahrokhi 
et al., 2013). Its administration protects the develop-
ment of type II collagen-induced arthritis in mice by 
modifying the immune responses (Hasegawa et al., 
2004). MSM also shows anti-apoptotic effects be-
cause dysregulation of apoptosis has been linked with 
various complications such as autoimmune, inflam-
matory and other diseases (Karabay et al., 2014). 
Thiocolchicoside (Th) is a semi-synthetic sul-
fur derivative of colchicoside, a naturally occurring 
glucoside derived from the plant Gloriosa superba 
(Umarkar et al., 2011). It has been used clinically as 
a muscle relaxant, anti-inflammatory, and analgesic 
drug (Umarkar et al., 2011; Soonawalla and Joshi, 
2008; Kumar et al., 2014; Lahoti, 2012) for the treat-
ment of orthopedic, traumatic and rheumatological 
disorders (Sandouk et al., 1994). Th significantly sup-
pressed enhanced osteoclastogenesis (Reuter et al., 
2012), which is an important pathological feature in 
many age-associated bone diseases including RA and 
osteoarthritis (Phan et al., 2004; Reuter et al., 2012). 
The phytoconstituents that present in the Gloriosa su-
perba show analgesic, anti-inflammatory and wound 
healing action in rats (John et al., 2010; Joshi et al., 
2010). Colchicine, an analog of colchicoside, is also a 
commonly used drug, especially for rheumatic diseas-
es (Efe et al., 2011).
We investigated the effects of MSM and MTh, be-
cause to our knowledge, there is no evidence to con-
firm this issue in detail by using the combination of 
MSM and Th (compound MTh) by using adjuvant-in-
duced arthritis (AA) in rats which is an experimental 
model of RA and widely used for testing and develop-
ing anti-arthritic and anti-inflammatory agents. Treat-
ment with diclofenac (DF), a standard prescription 
drug used to treat RA, was used as reference for pur-
poses of comparison. 
MATERIALS AND METHODS
Reagents
Complete Freund’s adjuvant (CFA), 10% forma-
lin, spirit-formol, hematoxylin, eosin, picrofuxin, 
toluidine blue, methyl-green-pyronin-y, acetic acid, 
trichloracetic acid, orthophosphoric acid, thiobarbi-
turic acid, nitric acid, ferrous sulfate, ascorbic acid, 
ammonium molybdate, hydrogen peroxide were 
purchased from Sigma-Aldrich Chemie and Fluca 
Chemie GmbH (Germany), ketamidor from Richer 
Pharma AG (Wels, Austria), sedaxylan from Eurovet 
Animal Health B.V (Holland), and diclofenac (DF) - 
from Glaxo Wellcome. The enzyme-linked immuno-
sorbent assay (ELISA) kits for determination of IL-6 
and IL-17 were produced by Abcam®.
Animals 
57 adult male albino rats of 9-10 weeks old, 
weighing between 180 and 200 g were obtained from 
the breeding unit of the Department of Biomodels 
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of the State Research Institute Centre for Innovative 
Medicine, and used in two experiments of the present 
study. The animals were divided into 6 experimental 
groups (n = 7-10 per group) and one healthy animal 
group (n = 6), housed in plastic cages and maintained 
in a temperature-controlled (22 ± 2oC) environment 
with a relative humidity of 60% and a 12-h light/
dark cycle. The rats were allowed one week to adapt 
to their environment before initiation of the experi-
ments. They were given standard commercial rodent 
pellets and water was freely available for the duration 
of the study. Animal care and handling throughout the 
experimental procedures in this study was in accord-
ance with the Directive 2010/63/EU of the European 
Parliament and of the Council of 22 September 2010 
on the protection of animals used for scientific pur-
poses. All experimental protocols in this study were 
approved by the Lithuanian Laboratory Animal Use 
Ethical Committee for Animal Experiments under the 
State Food and Veterinary Service. 
Induction, treatment and assessment of adjuvant 
arthritis
Adjuvant arthritis (AA) was induced in 51 rats by 
a single intra-dermal injection of complete Freund’s 
adjuvant (CFA 0.1 ml) into the foot pad of left hind 
paw (Murunikara et al., 2014). 
Concentrations of compounds and DF sufficient to 
provide anti-inflammatory effects were selected based 
upon values reported in the literature and our prelim-
inary studies. In the first experiment 30 rats with AA 
were divided into 3 groups (10 animals per group), 
as follows: Group I - Rats received MSM (77 mg/
kg), Group II - Rats received DF (1 mg/kg), Group III 
- Rats without treatment served as the control group. 
In the second experiment 21 animal was divided into 
3 groups (7 rats per group): Group IV - Rats received 
MTh (38 mg/kg; Th dose in this preparation - 0.25 mg/
kg), Group V - DF (1 mg/kg), Group VI - Rats with-
out treatment served as the control group. AA rats in 
both experiments were medicated from day 0 to 17. All 
preparations were suspended in 0.5 ml of 1℅ starch gel 
and injected orally 5 days a week. Rats of the control 
groups received the same volume of the starch gel. Six 
healthy animals (Group VII) served as healthy control. 
Body weight and joint swelling were monitored three 
times a week. The anti-arthritic effect of MSM, MTh 
or DF was evaluated by measuring the paw volume 
plethysmometrically by using plethysmometer (PVP 
1001; Kent Scientific Corporation). The inhibition per-
centage of investigated indices was calculated for each 
animal group in comparison with the control AA group. 
Duration of experiment was 17 days. 
At the end of experimental period all animals were 
killed by decapitation and then blood was collected for 
the examination of ESR and leukocytes by using blood 
analyzer Picoscale (Hungary). Blood serum was col-
lected from each animal to isolate serum. The blood 
was centrifuged at 3000g for 10 min. and serum drawn 
and stored at -20oC. The internal organs were removed 
and weighted. The liver and the injected paws were 
used for the histopathological examination.
Histopathological examination
The liver and injected paws from AA and healthy 
rats were excised followed by routine fixation, decal-
cification, and paraffin embedding. Paraffin bees wax 
tissue blocks were prepared for sectioning at 5 micron 
thickness by sledge microtome. The obtained tissue 
sections were collected on glass slides, deparaffinized 
and stained with hematoxylin-eosin, picrofuxin, tolui-
dine blue, methyl-green-pyronin-y and safranin O for 
histopathological examination through the light micro-
scope. Histological assessment of changes in the liver, 
soft periarticular tissues, synovium and cartilage was 
performed. During the processing and analysis of the 
liver and joints, the pathologist was “blinded” to the 
animal groups and the drug treatments. Each parameter 
was scored on a 0 to 3 point scale, where 0 means the 
absence of changes, 0.5 - traces of changes, 1 - minimal 
changes, 2 - moderate changes, 3 - heavy changes. 
Determination of lipid peroxide level and catalase 
(CAT) activity in blood serum
Lipid peroxidation assessed as malondialdehide 
(MDA) levels in the blood serum, expressed as nmol/
ml, were determined by the thiobarbituric acid reaction 
at 532 nm spectrophotometrically by the method of 
Gavrilov and co-workers (1987). Catalase (CAT) ac-
tivity, expressed in nmol/L/min, was measured at 410 
nm as described by Koroliuk and co-authors (1988). 
Measurement of cytokines levels
Cytokines like IL-6 and IL-17 were measured in 
the serum of the control and experimental animals 
by using respective enzyme-linked immunosorbent 
assay (ELISA) kits specific for rats (ab119536-IL-17 
Rat ELISA Kit and ab119548-IL-6 Rat ELISA Kit) 
according to procedure recommended by manufac-
turer’s instructions (abcam®; UK). Each sample was 
assayed in duplicate. The concentrations of cytokines 
were determined with the help of a standard curve.
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Statistical analysis was done by one-way analysis 
of variance ANOVA using PRISM Software (Graph-
Pad Software, San Diego, CA, USA) and Student’s 
t-test. The nonparametric Mann-Whitney U test was 
used to evaluate the histological changes. All data 
were expressed as the mean ± SEM and considered to 
be statistically significant at P values smaller than or 
equal to 0.05. 
RESULTS
Effect of MSM and MTh on the body and organ’s 
weight 
The initial body weight of rats did not differ among 
the groups and slightly increased during the experi-
ment in all investigated groups although no signifi-
cant differences between the groups were observed 
(data not shown). 
Significant increase of the liver, kidney and spleen 
weight and decrease of the thymus weight were ob-
served in rats with AA compared with the healthy an-
imals (Table 1). 
In the first experiment rats treated with MSM 
(group I) or DF (group II) showed only a significant 
decrease of the relative kidney weight (MSM - P < 
0.05; DF - P < 0.001) in comparison with the ani-
mals of the control group III. The relative weights of 
the liver were the same as in the healthy rats, but the 
spleen weight was significantly higher and the thymus 
weight was lower in both treated groups than those in 
the group of healthy animals.
In the second experiment rats treated with MTh 
(group IV) showed a significantly lower the relative 
weight of the liver (P < 0.02) and markedly higher 
weight of the thymus (P < 0.01) than those in the con-
trol VI group. The same effect was found after the 
treatment of AA with DF (liver - P < 0.01; thymus - P 
< 0.001).
Histopathological changes in the liver
There was no histopathological alteration and the 
normal histological structure of hepatic parenchyma 
was recorded in the liver sections of healthy animals 
(data not shown). 
The effect of MSM on the liver of rats with AA 
was similar to the effect of diclofenac (Table 2). Both 
preparations MSM and DF significantly decreased 
inflammatory infiltration of hepatic stroma with lym-
phocytes by 50.6% (P < 0.01) and 56.8% (P < 0.01) 
and the general inflammatory reaction by 38.7% (P 
< 0.05) and 48.1% (P < 0.05) respectively in com-
parison with the control AA group. Preparation MTh, 
diminished alteration of parenchyma by 28.8% (P < 
0.02), infiltration of hepatic stroma with lymphocytes 
by 80.9% (P < 0.02), macrophages by 79% (P < 0.05) 
and general inflammatory reaction by 64.2% (P < 
0.05). The penetration of inflammatory cells into the 
lobule decreased by 88.3% compared to the control 
AA group (P < 0.05). The effect of MTh on the liver 
was similar to the effect of DF except infiltration with 
macrophages, where this preparation didn’t show 
the significant decrease. So, after the treatment with 
MSM and MTh no toxic effects on the liver were ob-
served, and they improved histopathological changes 
in this organ caused by AA. It should be noted that the 
effect of MTh was more significant than that of MSM 
although it was used in twice lower dose.
          Table 1. Effect of MSM and MTh on relative organ’s weight
 Experiment Groups  Liver (g/kg-1)  Kidney (g/kg-1)  Spleen (g/kg-1)  Thymus (g/kg-1)
First
IAA + MSM 3.24±0.11 0.88±0.03 * + 0.45±0.03 + 0.124±0.010
II AA + DF 2.95±0.07 * 0.86±0.02 * + 0.40±0.01 * 0.166±0.016 *
IIIAA control + 3.46±0.13 + 0.96±0.02 + 0.51±0.03 + 0.110±0.010
 Second
IVAA+ MTh 3.45±0.22 * + 0.91±0.02 + 0.64±0.07 + 0.120±0.009 *
V AA + DF + 3.50±0.13 * 0.88±0.02 + 0.58±0.05 + 0.130±0.009 *
VIAA control + 4.39±0.24 + 1.00±0.05 + 0.88±0.10 + 0.080±0.008
Healthy rats 3.05±0.10 0.84±0.02 0.25±0.01 0.170±0.016
Note: Adjuvant arthritis (AA) was induced by a single injection of 0.1 ml of complete Freund‘s adjuvant (CFA) into the left hind 
paw. I group was treated prophylactically (since AA inducing day) with 77 mg/kg of methylsulfonylmethane (MSM) and IV group 
with 38 mg/kg of MTh (MSM and thiocolchicoside (Th) complex). II and V groups in both experiments were treated with 1 mg/
kg of diclofenac (DF). Preparations were suspended in the 1℅ starch gel and injected orally 5 times a week in a volume of 0.5 ml. 
Controls AA groups (III and VI gr.) received the same volume of the starch gel. * The differences are significant in comparison with 
the control group. + The differences are significant in comparison with the healthy animal’s group.
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There was a significant increase in ESR and leu-
kocyte’s count of arthritic rats in both experiments 
when compared with the healthy rats (Fig. 1A). MSM 
and MTh significantly reduced ESR by 48.7% (P < 
0.01) and 41.2% (P < 0.001), and leukocyte’s count 
by 41.2% (P < 0.001) and 24.6% (P < 0.02) respec-
tively compared with due control groups.
Effect of MSM and MTh on AA induced 
alterations in lipid peroxidation and antioxidant 
enzyme CAT activity
AA (Groups III and VI) induced serum lipid per-
oxidation reflected by a significant increase in MDA 
level compared with the healthy control (Fig. 1B). 
This was also accompanied by a significant 39.9% 
decrease in CAT activity in the first experiment and 
by 44.7% in the second experiment. Treatment with 
MSM (Group II) caused a significant 44.8% (P < 
0.0001) reduction in MDA level as a 20.3% elevation 
in CAT activity compared to the control AA group III. 
It should be noted that the effect of MSM and DF on 
MDA and CAT activity was similar. 
Although the administration of MTh for the treat-
ment of AA (Group IV) didn’t induce a significant 
change in CAT activity (it insignificantly increased 
by 27.2% and the differences between the treated and 
the control group was near to significant - t = 1.86), 
it markedly (P < 0.001) decreased MDA level in the 
blood serum by 58% in comparison with the control 
AA group VI. 
Effect of MSM and MTh on pro-inflammatory 
cytokines in blood serum of rats with AA
The cytokines in the serum were detected on day 
17 after immunization with CFA. We couldn’t to de-
tect IL-6 in the blood serum of healthy, tested and 
the control animals. MSM and MTh suppressed IL-
17 level by 22.58% and 27.9% respectively but they 
didn’t induce the significant changes compared to the 
control AA groups (Fig. 1C). 
Effect of AA treatment with MSM and MTh on 
the joint swelling
Effect of both preparations on joint swelling was 
not more effective than DF (Fig. 2). MSM signifi-
cantly decreased joint swelling only on days 3 (P < 
0.001) and 13 (P < 0.05), and at the end of experiment 
this suppression reached 19.6% in comparison with 
the control group III (Fig. 2A). MTh suppressed joint 
swelling till day 10 (P < 0.05-0.002) and on day 15 (P 
< 0.02) (Fig. 2B). So, preparation MTh was signifi-
cantly active on all the days in the acute phase of AA. 
Table 2. Effects of MSM and MTh on the liver in AA rats 
Index
 Groups













Alteration of parenchyma 0.75±0.08 0.65±0.11 0.88±0.15 1.21±0.10 * 0.71±0.10 * 1.70±0.12





Lymphocytes 0.40±0.10 * 0.35±0.11 * 0.81±0.09 0.21±0.10 * 0.14±0.09 * 1.10±0.29
Granulocytes 0.10±0.06 0 0.13±0.08 0.21±0.15 0 0.30±0.20
Macrophages 0.90±0.12 0.70±0.18 0.88±0.16 0.21±0.15 * 0.29±0.15 1.00±0.31
General 0.65±0.13 * 0.55±0.17 * 1.06±0.11 0.43±0.17 * 0.29±0.15 * 1.20±0.30
Penetration 
into the lobule 0.75±0.13 0.45±0.20 0.56±0.17 0.14±0.14 * 0.14±0.14 * 1.20±0.37
Note: Adjuvant arthritis (AA) was induced by a single injection of 0.1 ml complete Freund‘s adjuvant (CFA) into the left hind paw. I 
group (n = 10) was treated prophylactically (since AA inducing day) with 77 mg/kg of methylsulfonylmethane (MSM) and IV group 
(n =7) with 38 mg/kg of MTh ((MSM and thiocolchicoside (Th) complex). II (n = 10) and V (n = 7) groups in both experiments were 
treated with 1 mg/kg of diclofenac (DF). Preparations were suspended into the starch gel and injected orally 5 times a week in a 
volume of 0.5 ml. Controls AA groups (III and VI gr.) received the same volume of the starch gel. Duration of experiment is 17 days. 
Hepatic tissue was fixed in spirit-formol (1:9), embedded in paraffin, and 5 μm-thick histological sections of the tissue were stained 
with haematoxylin-eosin (for visualization of inflammation and inflammatory cell infiltration and necrosis of hepatocytes). The 
histological assessment of changes in the liver was performed in a blinded manner by pathologist. Each parameter was scored on a 0 
to 3 point scale, where 0 means the absence of changes, 0.5 - traces of changes, 1 - minimal changes, 2 - moderate changes, 3 - heavy 
changes. * The differences are significant in comparison with the control group. 
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Figure 1. Blood indices (A), pro-/antioxidant activities (B) and level of interleukin-17 (C) in rats with adjuvant arthritis treated with 
preparations MSM and MTh.
Adjuvant arthritis (AA) was induced by a single injection of 0.1 ml complete Freund‘s adjuvant (CFA) into the left hind paw. I group (n 
= 10) was treated prophylactically (since AA inducing day) with 77 mg/kg of methylsulfonylmethane (MSM) and IV group (n =7) with 
38 mg/kg of MTh ((MSM and thiocolchicoside (Th) complex). II (n = 10) and V (n = 7) groups in both experiments were treated with 
1 mg/kg of diclofenac (DF). Preparations were suspended into the starch gel and injected orally 5 times a week in a volume of 0.5 ml. 
Controls AA groups (III and VI gr.) received the same volume of the starch gel. * Differences are statistically significant in comparison 
with the control group. + Differences are statistically significant in comparison with healthy rats.
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Figure 2. Joint swelling of rats with adjuvant arthritis treated with preparations MSM (A) and MTh (B). 
Adjuvant arthritis (AA) was induced by a single injection of 0.1 ml complete Freund‘s adjuvant (CFA) into the left hind paw. I group (n 
= 10) was treated prophylactically (since AA inducing day) with 77 mg/kg of methylsulfonylmethane (MSM) and IV group (n =7) with 
38 mg/kg of MTh ((MSM and thiocolchicoside (Th) complex). II (n = 10) and V (n = 7) groups in both experiments were treated with 
1 mg/kg of diclofenac (DF). Preparations were suspended into the starch gel and injected orally 5 times a week in a volume of 0.5 ml. 
Controls AA groups (III and VI gr.) received the same volume of the starch gel. * Differences are statistically significant in comparison 
with the control group.
Effect of MSM and MTh treatment on histological 
findings in the joints
There were no abnormalities in the joints of healthy 
rats (data not shown). CFA administered control 
groups showed thinning of cartilage, erosions, pannus 
formation, extensive infiltration of inflammatory cells 
in the soft periarticular tissues and synovium.
MSM and MTh decreased inflammatory infiltra-
tion in the soft periarticular tissues (Table 3). Signifi-
cantly lower infiltration with macrophages (P < 0.02) 
was observed after the treatment with MSM and leu-
kocytes (P < 0.0001) - with MTh. Both preparations 
decreased general inflammatory reaction: MSM by 
36.6% (P < 0.001) and MTh by 21.3% (P < 0.0001) 
compared with the control arthritic groups. Suppres-
sion of edema and angiomatosis was also observed, 
although this supression was some lower than by 
using diclofenac. MSM markedly suppressed edema 
and angiomatosis by 49% (P < 0.001) and 46.6% (P 
< 0.002) and MTh by 33% (P < 0.001) and 31% (P < 
0.01) respectively in comparison with the control AA 
groups. 
The highest pathological changes in the synovium 
were found in the control AA groups. Both investi-
gated preparations MSM and MTh significantly sup-
pressed synovium villy proliferation. Proliferation 
decreased by 38.6% in MSM group (P < 0.001) and 
by 29.6% in MTh group (P < 0.02). Significant differ-
ences among the treated and the control AA groups 
were observed after evaluation of synovium edema, 
where marked decrease of it by 42.7% vs control was 
found in the group that received MSM (P < 0.05) and 
by 46.5% (P < 0.001) in the group treated with MTh. 
Preparation MSM significantly decreased synovium 
inflammatory infiltration with macrophages by 73.3% 
and it was the same as the action of DF (P < 0.001), 
and preparation MTh - infiltration with leukocytes by 
51.9% (P < 0.05). General inflammatory reaction in 
synovium was lower by 37.5% (P < 0.02) than in the 
control AA group after the treatment with MSM and 
by 35.6% (P < 0.01) in animals treated with MTh. Dif-
ferently than MSM, preparation MTh significantly di-
minished angiomatosis in synovium tissue by 48.5% 
(P < 0.01).
http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 23/08/2021 03:14:45 |
J HELLENIC VET MED SOC 2019, 70(2)
ΠΕΚΕ 2019, 70(2)
1568
Alone MSM in dose of 77 mg/kg showed more 
pronounced effect on cartilage than combined prepa-
ration MTh in twice lower dose. There were no fis-
sures in all the tested groups of animals in the first 
experiment. Erosium (P < 0.001) and usures (P < 
0.05) significantly decreased in MSM group. Both 
preparations MSM and MTh significantly suppressed 
pannus formation compared with the control groups: 
MSM induced 65% suppression (P < 0.05) and MTh 
- 32.6% suppression (P < 0.05). Traces of cartilage 
thinning was observed only in two animals treated 
with MSM, but no significant changes were observed 
in comparison with the control AA group. MTh sig-
nificantly decreased thinning of cartilage by 67.7% (P 
< 0.05), although this effect was lesser than effect of 
DF. 
DISCUSSION
RA is presently one of the most predominant dis-
eases worldwide. However, unfortunately, there has 
been no specific cure for RA. Because current treat-
ments for arthritis result in unwanted side effects and 
tend to be expensive, natural products devoid of such 
disadvantages offer a novel opportunity. Through this 
study, we have demonstrated that the supplementation 
of compounds such as MSM and MTh, could play a 
role in protecting against biochemical, immunolog-
ical and histological alterations in AA rats. The re-
sults of our study suggest that the prophylactic use of 
MSM and its combination with Th (compound MTh) 
in twice lower dose may have a significant effect on 
slowing disease progression although this therapeutic 
effect was not stronger than the effect of DF. MTh and 
Table 3. Histopathological changes in the joints after the treatment of AA with MSM and MTh
Tissue Index



















Lymphocytes 1.05±0.09 0.90±0.19 1.19±0.26 1.14±0.14 0.71±0.10 * 1.50±0.18
Leukocytes 1.10±0.23 0.60±0.18 * 1.63±0.29 2.36±0.09 * 1.21±0.21 * 3.00±0.00
Macrophages 0.60±0.10 * 0.90±0.12 1.00±0.09 1.14±0.18 0.86±0.09 * 1.67±0.17
General 1.35±0.11 * 1.35±0.08 * 2.13±0.08 2.36±0.09 * 1.36±0.09 * 3.00±0.00
Edema 1.05±0.09 * 0.65±0.11 * 2.06±0.11 1.79±0.10 * 0.71±0.15 * 2.67±0.17
Angiomatosis 0.70±0.08 * 0.65±0.08 * 1.31±0.13 1.78±0.15 * 0.57±0.07 * 2.58±0.20
Synovium
Proliferation 1.00±0.10 * 0.80±0.08 * 1.63±0.21 1.64±0.18 * 0.86±0.14 * 2.33±0.17
Edema 0.75±0.13 * 0.25±0.11 * 1.31±0.09 1.07±0.20 0.36±0.14 * 2.00±0.00
Inflammatory 
infiltration
Lymphocytes 0.55±0.12 0.35±0.13 * 0.94±0.20 1.14±0.09 0.36±0.09 0.83±0.21
Leukocytes 0.75±0.13 0.25±0.11 * 1.13±0.23 1.00±0.27 * 0.36±0.21 * 2.08±0.35
Macrophages 0.20±0.08 * 0.20±0.08 * 0.75±0.09 1.07±0.13 0.50±0.11 * 1.17±0.21
General 0.90±0.12 * 0.55±0.12 * 1.44±0.15 1.50±0.15 * 0.71±0.15 * 2.33±0.17
Angiomatosis 0.75±0.08 0.40±0.10 * 1.25±0.23 1.07±0.20 * 0.57±0.17 * 2.08±0.20
Cartilage
Erosium 0.80±0.20 * 0.65±0.15 * 2.00±0.00 2.00±0.00 2.00±0.00 2.00±0.00
Usura 0.30±0.13 * 0.20±0.11 * 1.06±0.27 1.28±0.18 0.21±0.10 * 1.50±0.22
Fissura 0 0 0 0.64±0.18 0 0.50±0.34
Pannus 0.35±0.11 * 0.05±0.05 * 1.00±0.27 1.57±0.20 * 0.43±0.23 * 2.33±0.21
Thinning of cartilage 0.10±0.06 0.05±0.05 0.38±0.16 0.43±0.17 * 0.07±0.07 * 1.33±0.36
Note: Adjuvant arthritis (AA) was induced by a single injection of 0.1 ml complete Freund‘s adjuvant (CFA) into the left hind paw. I 
group (n = 10) was treated prophylactically (since AA inducing day) with 77 mg/kg of methylsulfonylmethane (MSM) and IV group 
(n =7) with 38 mg/kg of MTh (MSM and thiocolchicoside (Th) complex). II (n = 10) and V (n = 7) groups in both experiments were 
treated with 1 mg/kg of diclofenac (DF). Preparations were suspended into the starch gel and injected orally 5 times a week in a 
volume of 0.5 ml. Controls AA groups (III and VI gr.) received the same volume of the starch gel. * The differences are significant in 
comparison with the control group. 
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to a lesser extent MSM, were found to inhibit joint 
swelling and the treatment with both preparations was 
also associated with decreased histological changes in 
joints. The main pathological changes of RA are that 
leukocytes infiltrate into articular cavity, cause recur-
rent synovitis (Cooles and Isaacs, 2011) and that in-
vasive pannus forms to damage cartilage, bone and 
surrounding tissue. In our study, compound MTh sig-
nificantly decreased infiltration with leukocytes in the 
soft periarticular tissues and synovium. 
It is known that MSM is one of the most popular 
dietary supplements, which is expected to relieve in-
flammation in arthritis. Recently, it has been shown 
that orally pretreatment of rats with MSM (400 mg/
kg) exhibits a hepato-protective effect against carbon 
tetrachloride induced acute liver injury by suppress-
ing pro-inflammatory cytokine release and apoptotic 
Bax/Bcl-2 ratio and increasing antioxidant enzyme 
levels (Kamel and Morsy, 2013). MSM is used as sin-
gly or in combination with other nutrients in dietary 
supplements for OA because sulfur is needed for for-
mation of connective tissue. 
In our study we combined MSM with Th (complex 
MTh). The latter has been used clinically as a mus-
cle relaxant, anti-inflammatory, and analgesic drug 
(Umarkar et al., 2011; Soonawalla and Joshi, 2008; 
Kumar et al., 2014; Lahoti, 2012) for the treatment 
of orthopedic, traumatic and rheumatologic disorders 
(Sandouk et al., 1994). We indicated a successful an-
ti-arthritic activity of this combined preparation. It is 
interesting that MTh in twice lower dose than MSM 
alone exerted inhibitory effect on the development of 
AA. 
No particular behavior, clinical or physiological 
signs were observed in animals treated with both 
compounds, suggesting that used preparation’s doses 
are probably not toxic in vivo. It was confirmed also 
by histological examination of the liver, where signif-
icantly lower alterations of hepatic parenchyma and 
stroma were found in the treated groups.
Increase in leukocyte count has been suggested 
to be one of the characteristic diagnoses of arthritis. 
In our present study, arthritic animals showed ele-
vated leukocyte level. MSM and MTh significantly 
decreased leukocytes, revealing their beneficial role 
against arthritis. ESR which significantly increased 
in arthritic control groups has been remarkably de-
creased after the treatment with both preparations and 
standard drug DF, thus justifying significant role of 
preparations in arthritic conditions. 
ROS in arthritis is not surprising since oxidative 
stress or ROS serve as mediators of tissue damage 
(Jayadevi et al., 2013). Antioxidant enzymes are pres-
ent in biological systems to protect the tissue from ox-
idative injury (Sabina and Rasool, 2008). Our results 
demonstrated that the activity of CAT was decreased 
in AA animals, which may have been due to increased 
production of free radicals. The decrease in anti-oxi-
dant enzyme activity correlated with increased lipid 
peroxidation quantified by measurement of the MDA. 
It is well known that MDA is a terminal product of 
lipid peroxidation and so the content of MDA can 
be used to estimate the extent of lipid peroxidation 
(Huang et al., 2012; Messarah et al., 2010). Elevat-
ed levels of MDA have been reported in the serum, 
liver and synovial fluid in patients with RA (Sarban 
et al., 2005). The increased levels of MDA may be 
due to its release from neutrophils and monocytes 
during inflammation. It appeared that the antioxidant 
defense was compromised in the AA and other kinds 
of arthritis as evidenced by increased MDA concen-
trations and decreased antioxidant enzyme CAT ac-
tivity (Huang et al., 2012). In our study biochemical 
assessments showed attenuated lipid peroxidation and 
increased CAT activity after the treatment with prepa-
rations MSM and MTh as compared to the control AA 
groups. Taken together, our results prove some anti-
oxidant action of these compounds. May be higher 
doses of MSM and MTh in our experiments could be 
used to achieve more pronounced antioxidant activity. 
Data on therapeutic effects of MSM and MTh led 
us to assay the ability of these preparations to prevent 
AA development in rats. These findings are consistent 
with those reported by other authors (Huang et al., 
2012; Kamel and El Morsy, 2013), who also showed 
an ability of MSM or Th to reduce inflammation and 
to enhance antioxidant enzyme activity and induction 
of direct scavenging of free radicals. 
It is known that pro-inflammatory cytokines such 
as TNF-α, IL-6, IL-17 play an important role in RA. 
Cytokines observed to be induced in the early phases 
following exposure to CFA are TNF-α, IL-12, IL-6, 
IFN-γ and several chemokine’s (Billiau and Matthys, 
2001). IL-6 is cytokine likely to be induced by CFA 
that may be relevant to induction of autoimmune dis-
eases. But as state Billiau and Matthys (2001), direct 
in vivo demonstration of IL-6 production following 
injection of CFA is not available, that also showed our 
investigations. 
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Another cytokine IL-17, a major product of T 
cells, plays the important role as an upstream media-
tor of RA pathogenesis. It promotes inflammation via 
enhancing the production of IL-1β, TNF-α and IL-6 
(Zhang et al., 2013; Shi et al., 2015). In our study, 
concentration of IL-17 significantly increased in the 
blood serum of rats with AA compared to the healthy 
control, and its reduction was demonstrated in re-
sponse to MSM and MTh. Although no significant 
differences were found in the serum concentrations of 
IL-17, both preparations had a tendency to reduce this 
cytokine level compared with the control AA groups. 
Data discussed above suggest that the anti-arthritic 
effect of investigated compounds could occur through 
the inhibition of oxidative stress in AA and increased 
antioxidant activity after the treatment.
CONCLUSIONS
This study has demonstrated that the oral admin-
istration of MSM or its combination with Th (com-
pound MTh) attenuates the development of AA in 
rats. Compounds had an inhibitory effect on joint 
swelling in AA model induced by CFA injection. This 
correlated with attenuation of histological changes in 
injected joints, decreased level of IL-17, together with 
significantly lower levels of MDA and increased CAT 
activity. These therapeutic benefits were comparable 
with those achieved by treating with the clinically 
available drug, diclofenac. MSM alone and in combi-
nation with Th (compound MTh) can be the safe and 
well tolerated dietary supplements that are two im-
portant parameters for the promising drug candidates 
for joint diseases therapy. These are the first data to 
indicate successful anti-arthritic activity of combined 
MTh preparation. Findings provide clues that inves-
tigated compounds may be the promising agents for 
preventing and treating of autoimmune diseases in 
combination with other drugs.
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